OUR VISION OF THE FUTURE: Arizona is a top-ten life science state.

OUR MISSION: AZBio supports the needs of Arizona’s growing life science ecosystem.

Arizona’s bioscience industry employed 40,399 in 2023 across 3,652 state business establishments, representing a rapid 24.6 percent increase in employment since 2019 and placing the state among the leaders in employment growth. The average wage in the bioscience industry was $102,161—53 percent higher than the state’s private sector average. Academic R&D expenditures in bioscience fields reached a new height of $683.3 million in 2022. NIH funding for Arizona totaled $366.5 million in 2023 following steady annual growth since 2019. Arizona’s bioscience companies attracted strong venture capital investment, with $281.8 million invested in 2023. Arizona stands out in patent activity in bioscience-related technology areas—its 3,387 patent awards from 2019 through 2023 places the state in the second quintile among all states. AZ-BIO2024 - state profile

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on growing Arizona’s bioscience industry.

AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.

AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations.

Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.

Critical Path Institute Appoints Dr. Aoife Brennan to Board of Directors

TUCSON, Ariz., July 16, 2025 — Critical Path Institute® (C-Path) today announced the appointment of Aoife Brennan, M.D., to its Board of Directors. Dr. Brennan brings extensive experience in biopharmaceutical leadership, clinical development, and regulatory strategy to C-Path’s growing efforts to advance global drug development and data-driven science.

C-Path’s Translational Therapeutics Accelerator Announces $200,000 Grant for Drug Development Project in Inflammatory Bowel Disease

University Hospitals Cleveland Medical Center physician awarded funding to advance novel therapy for IBD.

The R & D Expensing Fix in the One Big Beautiful Bill

New tax law restores immediate R&D expensing in the US

C-Path’s Kristen Swingle Named a “Woman Leading the Region” by BizTucson

TUCSON, Ariz., July 9, 2025 — Critical Path Institute® (C-Path) is proud to announce that President and Chief Operating Officer Kristen Swingle, M.S., has been named a 2025 BizTucson “Woman Leading the Region,” an honor recognizing Southern Arizona’s most impactful women in leadership, innovation, and community advancement.